TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDAZacks Investment Research • 01/14/26
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law FirmGlobeNewsWire • 01/13/26
SHAREHOLDER ALERT: Travere Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Should Contact The FirmGlobeNewsWire • 01/13/26
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGSBusiness Wire • 01/13/26
Travere Therapeutics Hammered On A Potential, Surprise Delay For FilspariInvestors Business Daily • 01/13/26
Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/26
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025Business Wire • 11/06/25
Top 2% Travere Looks To Top Buy Zone After Screaming Up Another BeatInvestors Business Daily • 10/31/25
Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/30/25
Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 10/30/25
Biotech Leader Travere Therapeutics Eyes Buy Point After More Than DoublingInvestors Business Daily • 10/23/25
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025Business Wire • 10/17/25